HR 2038
116th Congress
House
Health
Cancer
Child health
Child safety and welfare
Congressional oversight
Drug, alcohol, tobacco use
Health care costs and insurance
Health care coverage and access
Health facilities and institutions
Health personnel
Health programs administration and funding
Long-term, rehabilitative, and terminal care
Prescription drugs
Rural conditions and development
Sales and excise taxes
State and local finance
State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019
Introduced: April 2, 2019
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 15, 2019
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Apr 2, 2019
Referred to the House Committee on the Judiciary.
Apr 2, 2019
Introduced in House
Plain-English summary
State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019
This bill authorizes health insurance issuers to jointly negotiate the prices for prescription drugs with the manufacturers of such drugs.
What's happening now
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Committees of jurisdiction
2
Cosponsors
1